EIF2B4 and neoplasm: By integrating TCGA cohort analyses, functional experiments, and in vivo models, we provide the first clinical evidence linking elevated EIF2B4 expression to poor HCC prognosis, while mechanistically implicating its translational regulatory role in tumor progression and immune evasion.